Metastatic
melanoma has poor prognosis and is refractory to most conventional
chemotherapies. The
alkylating agent temozolomide (TMZ) is commonly used in treating
melanoma but has a disappointing response rate. Agents that can act cooperatively with TMZ and improve its efficacy are thus highly sought after. The BH3 mimetic
ABT-737, which can induce apoptosis by targeting pro-survival Bcl-2 family members, has been found to enhance the efficacy of many conventional chemotherapeutic agents in multiple
cancers. We found that combining TMZ and
ABT-737 induced strong synergistic apoptosis in multiple human
melanoma cell lines. When the drugs were used in combination in a mouse xenograft model, they drastically reduced
tumor growth at concentrations where each individual
drug had no significant effect. We found that TMZ treatment elevated p53 levels, and that the
pro-apoptotic protein Noxa was elevated in TMZ/ABT-737 treated cells. Experiments with
shRNA demonstrated that the synergistic effect of TMZ and
ABT-737 was largely dependent on Noxa. Experiments with
nutlin-3, a p53 inducer, demonstrated that p53 induction was sufficient for synergistic cell death with
ABT-737 in a Noxa-dependent fashion. However, p53 was not necessary for TMZ/ABT-737 synergy as demonstrated by a p53-null line, indicating that TMZ and
ABT-737 together induce Noxa in a p53-independent fashion. These results demonstrate that targeting anti-apoptotic Bcl-2 members is a promising method for treating metastatic
melanoma, and that clinical trials with TMZ and Bcl-2 inhibitors are warranted.